Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
NASDAQ:FGEN
FGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.18 - $1.53
Previous CloseN/A
Volume937.77K
Average Volume (3M)692.99K
Market Cap
$30.92M
Enterprise Value$53.73M
Total Cash (Recent Filing)$50.48M
Total Debt (Recent Filing)$73.09M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Aug 11, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding101,043,970
10 Day Avg. Volume768,037
30 Day Avg. Volume692,992
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.14
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap1.74
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit3.82
Enterprise Value/Ebitda-0.09
Forecast
1Y Price Target
$10.00Price Target Upside3125.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
FibroGen News
PremiumCompany Announcements
FibroGen’s Earnings Call: Strategic Gains Amid Revenue Woes
PremiumCompany Announcements
FibroGen Reports Q1 2025 Earnings and Strategic Updates
PremiumPre-Earnings
Is FGEN a Buy, Before Earnings?
PremiumCompany Announcements
FibroGen’s Earnings Call: Strategic Moves Amid Challenges---
Bulls Say, Bears Say
Bulls Say
Financial HealthThe strategic transaction with AstraZeneca is anticipated to extend FibroGen's cash runway into 2027, bolstering its financial health amid challenging macro conditions.
Revenue StabilityRoxadustat's approval in 45 countries for treating anemia provides a stable revenue stream and reduces the need for dilutive capital raises.
Strategic DevelopmentFibroGen remains increasingly focused on progressing its primary therapeutic candidate, FG-3246, with multiple studies providing several opportunities for success.
Bears Say
Legal And Regulatory ChallengesAnnounced a settlement related to roxadustat, which will result in a $1.25 million civil penalty paid to FibroGen.
Operational RisksFeedback from meeting with the FDA to discuss next steps for roxadustat in anemia associated with low-risk myelodysplastic syndrome now expected in the third quarter.
---
Ownership Overview
1.78% Insiders
10.90% Mutual Funds
13.04% Other Institutional Investors
69.52% Public Companies and Individual Investors
FGEN FAQ
What was FibroGen’s price range in the past 12 months?
FibroGen lowest stock price was $0.18 and its highest was $1.53 in the past 12 months.
What is FibroGen’s market cap?
FibroGen’s market cap is $30.92M.
When is FibroGen’s upcoming earnings report date?
FibroGen’s upcoming earnings report date is Aug 11, 2025 which is in 84 days.
How were FibroGen’s earnings last quarter?
FibroGen released its earnings results on May 12, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.02.
Is FibroGen overvalued?
According to Wall Street analysts FibroGen’s price is currently Undervalued.
Does FibroGen pay dividends?
FibroGen does not currently pay dividends.
What is FibroGen’s EPS estimate?
FibroGen’s EPS estimate is -0.09.
How many shares outstanding does FibroGen have?
FibroGen has 101,043,970 shares outstanding.
What happened to FibroGen’s price movement after its last earnings report?
FibroGen reported an EPS of $0.05 in its last earnings report, beating expectations of $0.03. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of FibroGen?
Currently, no hedge funds are holding shares in FGEN
---
FibroGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (3125.81% Upside)
$10.00 (3125.81% Upside)
Blogger Sentiment
Bearish
FGEN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 5.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $153.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.32%
12-Months-Change
Fundamentals
Return on Equity
60.38%
Trailing 12-Months
Asset Growth
-54.84%
Trailing 12-Months
Company Description
FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
---
FGEN Company Deck
---
FGEN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a transformative period for FibroGen, with the sale of FibroGen China to AstraZeneca bringing in higher than expected proceeds and extending their financial runway significantly. There is notable progress in their clinical pipeline, particularly in the development of FG-3246 and FG-3180, with promising results from clinical trials. However, the company faced a significant decline in revenue and continued to operate at a net loss. While the highlights indicate strategic advancements and positive financial prospects, the revenue decline and continued net loss are concerning.Read More>---
FGEN Stock 12 Month Forecast
Average Price Target
$10.00
▲(3125.81% Upside)
Technical Analysis
---